New advances in the pathogenesis of ANCA-associated vasculitides

Clinical and Experimental Rheumatology

Volumn 27, Issue 1 SUPPL. 52, 2009, Pages

  Chen, Min ^a,b   Kallenberg, Cees G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

ANCA; Pathogenesis; Vasculitis

Indexed keywords

ADHESIN; COMPLEMENT COMPONENT C5A; COMPLEMENTARY PROTEINASE 3 ANTIBODY; CROSS REACTING ANTIBODY; HYDROLASE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; METHYLPREDNISOLONE; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PLASMINOGEN; PROTEIN ANTIBODY; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ANCA ASSOCIATED VASCULITIS; CD4+ T LYMPHOCYTE; DISEASE COURSE; ENDOTHELIUM CELL; GLOMERULONEPHRITIS; GRAM NEGATIVE BACTERIUM; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FAILURE; NEUTROPHIL; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SPLEEN CELL; TH1 CELL; TH17 CELL; TH2 CELL;

ANIMALS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BLOOD GROUP ANTIGENS; CELLS, CULTURED; CHURG-STRAUSS SYNDROME; DISEASE MODELS, ANIMAL; HUMANS; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; MICROSCOPIC POLYANGIITIS; PEROXIDASE; RATS; WEGENER GRANULOMATOSIS;

EID: 70450235126     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. JENNETTE JC, FALK RJ: Small-vessel vasculitis. N Engl J Med 1997; 337: 1512-1523
2. KALLENBERG CG: Churg-Strauss syndrome: just one disease entity? Arthritis Rheum 2005; 52: 2589-2593
3. HAGEN EC, DAHA MR, HERMANS J et al.: Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998; 53: 743-753
4. CHEN M, YU F, ZHANG Y, ZOU WZ, ZHAO MH, WANG HY: Characteristics of Chinese patients with Wegener's granulomatosis with anti-myeloperoxidase autoantibodies. Kidney Int 2005; 68: 2225-2229
5. CHEN M, YU F, WANG SX et al.: Renal histology in Chinese Patients with anti-myeloperoxidase autoantibodies positive Wegener's granulomatosis. Nephrol Dial Transplant 2007; 22: 139-145
6. CHEN M, YU F, ZHANG Y, ZHAO MH: Anti-neutrophil cytoplasmic autoantibodies associated vasculitis in older patients. Medicine (Baltimore) 2008, 87: 203-209
7. KAIN R, MATSUI K, EXNER M et al.: A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: the lysosomal membrane glycoprotein h-lamp-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cells. J Exp Med 1995; 181: 585-597
8. DAVIES DJ, MORAN JE, NIALL JF, RYAN GB: Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? BMJ 1982; 285: 606.
9. VAN DER WOUDE FJ, RASMUSSEN N, LOBATTO S et al.: Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; 1: 425-429
10. BANSAL PJ, TOBIN MC: Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol 2004; 93: 398-401.
11. SCHLIEBEN DJ, KORBET SM, KIMURA RE et al.: Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs. Am J Kidney Dis 2005; 45:758-761
12. JAYNE DR, GASKIN G, RASMUSSEN N et al.: Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18:2180-2188
13. DE LIND VAN WIJNGAARDEN RA, HAUER HA, WOLTERBEEK R et al.: Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis. J Am Soc Nephrol 2007; 18: 2189-2197
14. FALK RJ, NACHMAN PH, HOGAN SL, JENNETTE JC: ANCA glomerulonephritis and vasculitis: a Chapel Hill perspective. Semin Nephrol 2000; 20: 233-243
15. SAVAGE CO: ANCA-associated renal vasculitis. Kidney Int 2001; 60: 1614-1627
16. BOOMSMA MM, STEGEMAN CA, VAN DER LEIJ MJ et al.: Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000; 43: 2025-2033
17. STEGEMAN CA: Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitis. Nephrol Dial Transplant 2002; 17: 2077-2080
18. BIRCK R, SCHMITT WH, KAELSCH IA, VAN DER WOUDE FJ: Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. Am J Kidney Dis 2006; 47: 15-23.
19. FINKIELMAN JD, MERKEL PA, SCHROEDER D et al.: Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007; 147: 611-619
20. PENDERGRAFT WF 3RD, PRESTON GA, SHAH RR et al.: Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 2004; 10: 72-79
21. BAUTZ DJ, PRESTON GA, LIONAKI S et al.: Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. J Am Soc Nephrol 2008; 19: 2421-9.
22. STASSEN PM, DERKS RP, KALLENBERG CG, STEGEMAN CA: Venous thromboembolism in ANCA-associated vasculitis - incidence and risk factors. Rheumatology (Oxford). 2008; 47: 530-534
23. YANG J, BAUTZ DJ, LIONAKI S et al.: ANCA patients have T cells responsive to complementary PR-3 antigen. Kidney Int 2008; 74: 1159-1169
24. FALK RJ, TERRELL R, CHARLES LA, JENNETTE JC: Antineutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals. Proc Nat Acad Sci USA 1990; 87: 4115-4119
25. CHARLES LA, CALDAS MLR, FALK RJ et al.: Antibodies against granule proteins activate neutrophils in vitro. J Leuk Biol 1991; 50: 539-546
26. PORGES AJ, REDECHA PB, KIMBERLY WT et al.: Antineutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa. J Immunol 1994; 153: 1271-1280 (Pubitemid 24228519)
27. MULDER AH, HEERINGA P, BROUWER E et al.: Activation of granulocytes by antineutrophil cytoplasmic antibodies (ANCA): a Fc gamma RII-dependent process. Clin Exp Immunol 1994; 98: 270-276
28. HEWINS P, MORGAN MD, HOLDEN N et al.: IL-18 is upregulated in the kidney and primes neutrophil responsiveness in ANCA-associated vasculitis. Kidney Int 2006; 69: 605-615
29. GUILPAIN P, SERVETTAZ A, GOULVESTRE C et al.: Pathogenic effects of antimyeloperoxidase antibodies in patients with microscopic polyangiitis. Arthritis Rheum 2007; 56: 2455-2463
30. ZHANG AH, CHEN M, GAO Y, ZHAO MH, WANG HY: Inhibition of oxidation activity of myeloperoxidase (MPO) by propylthiouracil (PTU) and anti-MPO antibodies from patients with PTU-induced AAV. Clin Immunol 2007; 122: 187-193
31. CSERNOK E, HOLLE JU, GROSS WL: Proteinase 3, protease-activated receptor-2 and interleukin-32: linking innate and autoimmunity in Wegener's granulomatosis. Clin Exp Rheumatol 2008; 26 (Suppl. 49): S112-7.
32. SCHREIBER A, BUSJAHN A, LUFT FC, KETTRITZ R: Membrane expression of proteinase 3 is genetically determined. J Am Soc Nephrol 2003; 14: 68-75.
33. VAN ROSSUM AP, HUITEMA MG, STEGEMAN CA et al.: Standardised assessment of membrane proteinase 3 expression. Analysis in ANCA-associated vasculitis and controls. Ann Rheum Dis 2007; 66: 1350-1355
34. WITKO-SARSAT V, LESAVRE P, LOPEZ S et al.: A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis. J Am Soc Nephrol 1999; 10: 1224-1233
35. RAROK AA, STEGEMAN CA, LIMBURG PC, KALLENBERG CG: Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis. J Am Soc Nephrol 2002; 13: 2232-2238
36. BAUER S, ABDGAWAD M, GUNNARSSON L, SEGELMARK M, TAPPER H, HELLMARK T: Proteinase 3 and CD177 are expressed on the plasma membrane of the same subset of neutrophils. J Leukoc Biol 2007; 81: 458-464
37. VON VIETINGHOFF S, TUNNEMANN G, EULENBERG C et al.: NB1 mediates surface expression of the ANCA antigen proteinase 3 on human neutrophils. Blood 2007; 109: 4487-4493
38. HU N, WESTRA J, HUITEMA MG et al.: Co-expression of CD177 and membrane proteinase 3 on neutrophils in ANCA-associated systemic vasculitis: anti-PR3 mediated neutrophil activation is independent of the role of CD177-expressing neutrophils. Arthritis Rheum 2009; 60: 1548-1557
39. HESS C, SADALLAH S, SCHIFFERLI JA: Induction of neutrophil responsiveness to myeloperoxidase antibodies by their exposure to supernatant of degranulated autologous neutrophils. Blood 2000; 96: 2822-2827
40. MULLER A, TRABANDT A, GLOECKNER-HOFMANN K et al.: Localized Wegener's granulomatosis: Predominance of CD26 and IFNgamma expression. J Pathol 2000; 192: 113-120
41. LAMPRECHT P, BRUHL H, ERDMANN A et al.: Differences in CCR5 expression on peripheral blood CD4+. Clin Immunol 2003; 108: 1-7.
42. ABDULAHAD WH, STEGEMAN CA, LIMBURG PC, KALLENBERG CG: Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission. Arthritis Rheum 2008; 58: 2196-2205
43. IVANOV S, BOZINOVSKI S, BOSSIOS A et al.: Functional relevance of the IL-23-IL-17 axis in lungs in vivo. Am J Respir Cell Mol Biol 2007; 36: 442-451
44. LI H, NOOH MM, KOTB M, RE F: Commercial peptidoglycan preparations are contaminated with superantigen-like activity that stimulates IL-17 production. J Leukoc Biol 2008; 83: 409-418
45. ABDULAHAD WH, VAN DER GELD YM, STEGEMAN CA, KALLENBERG CG: Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosis. Kidney Int 2006; 70: 938-947 (Pubitemid 44285972)
46. XIAO H, HEERINGA P, HU P et al.: Anti-neutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110: 955-963
47. XIAO H, HEERINGA P, LIU Z et al.: The role of neutrophils in the induction of glomerulonephritis by antimyeloperoxidase antibodies. Am J Pathol 2005; 167: 39-45.
48. HUUGEN D, XIAO H, VAN ESCH A et al.: Aggravation of antimyeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol 2005; 167: 47-58.
49. SCHREIBER A, XIAO H, FALK RJ, JENNETTE JC: Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by antimyeloperoxidase antibodies. J Am Soc Nephrol 2006; 17: 3355-3364
50. LITTLE MA, SMYTH CL, YADAV R et al.: Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 2005; 106:2050-2058
51. PFISTER H, OLLERT M, FRÖHLICH LF et al.: Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 2004; 104: 1411-1418
52. VAN DER GELD YM, HELLMARK T, SELGA D et al.: Rats and mice immunised with chimeric human/mouse proteinase 3 produce autoantibodies to mouse Pr3 and rat granulocytes. Ann Rheum Dis 2007; 66: 1679-1682
53. SAVAGE CO, POTTINGER BE, GASKIN G, PUSEY CD, PEARSON JD: Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells. Am J Pathol 1992; 141: 335-342
54. RADFORD DJ, LUU NT, HEWINS P, NASH GB, SAVAGE CO: Antineutrophil cytoplasmic antibodies stabilize adhesion and promote migration of flowing neutrophils on endothelial cells. Arthritis Rheum 2001; 44: 2851-61.
55. NOLAN SL, KALIA N, NASH GB, KAMEL D, HEERINGA P, SAVAGE CO: Mechanisms of ANCA-mediated leukocyte-endothelial cell interactions in vivo. J Am Soc Nephrol 2008; 19: 973-984
56. LITTLE MA, SAVAGE CO: The role of the endothelium in systemic small vessel vasculitis. Clin Exp Rheumatol 2008; 26 (Suppl. 49): S135-40.
57. KAIN R, EXNER M, BRANDES R et al.: Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008; 14: 1088-1096
58. KALLENBERG CG, STEGEMAN CA, HEERINGA P: Autoantibodies vex the vasculature. Nat Med 2008; 14: 1018-1019
59. XIAO H, SCHREIBER A, HEERINGA P et al.: Alternative complement pathway in the pathogenesis of disease mediated by antineutrophil cytoplasmic autoantibodies. Am J Pathol 2007; 170:52-64.
60. HUUGEN D, VAN ESCH A, XIAO H et al.: Inhibition of complement factor C5 protects against antimyeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int 2007; 71: 646-654
61. SCHREIBER A, XIAO H, JENNETTE JC, SCHNEIDER W, LUFT FC, KETTRITZ R: C5a Receptor Mediates Neutrophil Activation and ANCA-Induced Glomerulonephritis. J Am Soc Nephrol 2009; 20: 289-298
62. CHEN M, XING GQ, YU F, LIU G, ZHAO MH: Complement deposition in renal histopathology of patients with ANCA-associated pauci-immune glomerulonephritis. Nephrol Dial Transplant 2009; 24: 1247-1252
63. XING GQ, CHEN M, LIU G et al.: Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol 2008; 29: 282-291
64. KALLENBERG CG, HEERINGA P, STEGEMAN CA: Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol 2006; 2: 661-670